This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dyke, C. M. Articles by Tamberella, M. R. Search for Related Content PubMed PubMed Citation Articles by Dyke, C. M. Articles by Tamberella, M. R., III Social Bookmarking                         What's this?

Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass

Carolina Cardiovascular and Thoracic Surgery Associates, Gaston Memorial Hospital, dykec{at}gmh.org

Lisa K. Jennings, PhD

Vascular Biology Center of Excellence, University of Tennessee Health Science Center, Memphis, Tennessee

George Maier, MD

Carolina Cardiovascular and Thoracic Surgery Associates, Gaston Memorial Hospital

Costa Andreou, MD

Mid-Carolina Cardiology, Gaston Memorial Hospital

Robert Daly, MD

Medifacts International, Rockville, Maryland

Michael R. Tamberella, III, MD

Carolina Heart Specialists, Gaston Memorial Hospital, Gastonia, North Carolina

Platelet glycoprotein IIb-IIIa antagonists reduce cardiac events in acute coronary syndromes (ACSs), but their use is limited during coronary artery bypass grafting (CABG) because of bleeding concerns. Patients with ACS, however, are at increased risk for cardiac events after CABG. The use of short-acting glycoprotein IIbIIIa inhibitor eptifibatide in patients with ACS undergoing CABG was investigated. Fifteen patients with ACS and undergoing CABG with cardiopulmonary bypass were enrolled. One withdrew before surgery. Patients received heparin and eptifibatide preoperatively. Eptifibatide concentration and receptor occupancy (RO) at termination of infusion were similar in the two groups. Immediately before surgery, eptifibatide levels in the 2-hour group were twice that in the 4-hour group, and platelet RO was higher. Cessation of eptifibatide 4 hours before surgery results in less bleeding and transfusions than 2 hours before surgery. The optimal balance between bleeding and platelet inhibition is approximately 60% platelet RO. Further investigation of upstream therapy should target this threshold.

Key Words: blood • anticoagulation • cardiopulmonary bypass • platelets

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 12, No. 1, 54-60 (2007)
DOI: 10.1177/1074248406299068


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?